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INTRODUCTION 
 
Tumor cell migration leads to metastasis, which is 
responsible for about 90% of deaths caused by cancer 
[1]. Signaling by a number of different growth factors, 
including EGF and PDGF, can activate the Src and Abl 
kinases in order to promote tumor cell invasion and 
metastasis [2,3]. Src and Abl are nonreceptor tyrosine 
kinases, that can inturn phosphorylate a variety of 
substrates, including Cas, Crk, and paxillin, to initiate 
cell spreading and migration [4-6]. Src phosphorylates 
Abl [2], which associates with actin and the Rho family 
of GTPases to modify effectors including N-WASP to 
promote cytoskeletal reorganization and cell motility 
[3,7,8]. However, Src also relies on parallel pathways 
to induce tumor cell growth and migration [9,10]. 
The Abl kinase can phosphorylate the Robo1 
receptor [11]. Robo1 is a transmembrane receptor of 
the immunoglobulin family [7,12]. Upon binding to its 
ligand, Slit2, Robo1 works with the Abl kinase to 
rearrange the actin cytoskeleton and induce cell 
migration [13,14]. Indeed, cell migration can be 
inhibited by blocking Robo1 receptor activity with a 
monoclonal antibody to the extracellular domain of the 
protein [14]. Hence, the Abl kinase provides a link 
                            
Src activates Abl to augment Robo1 expression in order to 
promote tumor cell migration 
 
P. Raaj Khusial
1, Bhaskar Vadla
1,2, Harini Krishnan
1,2, Trudy F. Ramlall
3, 
Yongquan Shen
1, Hitoshi Ichikawa
4, Jian-Guo Geng
5, and Gary S. Goldberg
1 
 
1 Molecular Biology Department, University of Medicine and Dentistry of New Jersey, Stratford, NJ  08084, USA 
2 Graduate School of Biomedical Sciences, University of Medicine and Dentistry of New Jersey, Stratford, NJ  08084, USA 
3 Department of Biochemistry and Program in Structural Biology, Weill Medical College of Cornell University, New York, New York  
10065, USA  
4 Genetcis Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan 
5 Vascular Biology Center, Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of 
Minnesota Medical School, Minneapolis, Minnesota 55455, USA 
 
Correspondence to:  Gary S Goldberg, e-mail: gary.goldberg@umdnj.edu 
 
Keywords: Tyrosine kinase, Src kinase Abl kinase, Robo1, Rho GTPase, Cancer, Cell migration, Cell communication, Connexin 
Received: June 15, 2010,    Accepted: July 16, 2010,   Published:  July 20, 2010 
Copyright: C 2010 Khusial et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
 
ABSTRACT: 
Cell migration is an essential step in cancer invasion and metastasis. A number of 
orchestrated cellular events involving tyrosine kinases and signaling receptors enable 
cancer cells to dislodge from primary tumors and colonize elsewhere in the body. For 
example, activation of the Src and Abl kinases can mediate events that promote 
tumor cell migration. Also, activation of the Robo1 receptor can induce tumor cell 
migration. However, while the importance of Src, Abl, and Robo1 in cell migration 
have been demonstrated, molecular mechanisms by which they collectively influence 
cell migration have not been clearly elucidated. In addition, little is known about 
mechanisms that control Robo1 expression. We report here that Src activates Abl to 
stabilize Robo1 in order to promote cell migration. Inhibition of Abl kinase activity by 
siRNA or kinase blockers decreased Robo1 protein levels and suppressed the 
migration of transformed cells. We also provide evidence that Robo1 utilizes Cdc42 
and Rac1 GTPases to induce cell migration. In addition, inhibition of Robo1 signaling 
can suppress transformed cell migration in the face of robust Src and Abl kinase 
activity. Therefore, inhibitors of Src, Abl, Robo1 and small GTPases may target a 
coordinated pathway required for tumor cell migration.  
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between Robo1 and the actin cytoskeleton. However, 
the role of Src kinase activity in this pathway has not 
been defined. 
Here, we describe a molecular relationship between 
Src, Abl, and Robo1 that promotes tumor cell 
migration. Our data indicate that Src activates the Abl 
kinase, which in turn, stabilizes the expression of 
Robo1 and increases GTPase activity to promote tumor 
cell migration. These results demonstrate how 
monoclonal antibodies and kinase inhibitors may be 
used to target specific components of the 
Src/Abl/Robo1 pathway to prevent tumor cell 
migration at multiple steps.  
 
RESULTS 
 
Src augments Robo1 production in transformed 
cells 
 
The Src kinase activates a variety of pathways that 
promote cell migration [9,10]. For example, data from 
previous experiments indicate that Src induces the 
expression of Slit2 [15] which binds to its receptor, 
Robo1, to promote cell migration [13,14,19,22]. We 
utilized expression microarrays to further investigate 
the effect of Src kinase activity on Slit2 mRNA 
expression. As shown in Figure 1a, these data indicate 
that Src transformed cells expressed over 4 times more 
Slit2 mRNA than nontransformed cells.  
As stated above, Slit2 is a secreted protein that 
binds to the Robo1 receptor [13,14,19,22]. Upon Slit2 
binding to Robo1 the activity of the Rho GTPases are 
regulated to rearrange the actin cytoskeleton and 
induce cell motility [7]. Therefore, if Slit2 were 
promoting tumor cell migration, Src may also be 
expected to increase Robo1 expression in transformed 
cells. However, Affymetrix microarray data indicate 
that Src transformed cells contained less Robo1 mRNA 
than nontransformed cells (Figure 1a). The suppression 
of Robo1 mRNA expression by Src was also confirmed 
by qRT-PCR as shown in Figure 1b.    
Src phosphorylates Cx43 to block gap junctional 
communication between transformed cells [23,24]. 
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Fig. 1: Src reduces Robo1 mRNA levels, but increases Robo1 protein levels. 
(a) mRNA was extracted from nontransformed and Src transformed Cx43Ko cells and examined by microarray
analysis. Expression values of Affymetrix probe sets representing Slit2 and Robo1 are shown (mean+SEM, n=2).
(b) Robo1 mRNA expression was examined by qRT-PCR analysis of RNA purified from nontransformed and Src
transformed cells obtained from wild type embryos (WT) or homozygous null Cx43 knockout embryos (Cx43Ko)
as indicated. Data are shown as the percent of nontransformed cells (mean+SEM, n=2). (c) Western blotting was 
used to compare the expression of Robo1, total Src, active Src, Cx43, Slit2, and β-actin in nontransformed and
Src transformed cells. Robo1 protein expression was quantitated from Western blot analysis of nontransformed 
and Src transformed cells and shown as percent of nontransformed cells (mean+SEM, n=3). Single and triple
asterisk indicate p values less than 0.5 and 0.005, respectively (by t-test).  
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Indeed, Cx43 can act as a tumor suppressor in a 
number of cell types including mammary carcinoma 
[25,26] and glioma cells [27-29]. In contrast, Robo1 
activity can promote glioma cell migration [30] and 
metastasis of breast cancer cells to the brain [31]. Thus, 
we sought to analyze the role of Robo1 in the 
migration of wild type mouse embryonic fibroblasts 
that express Cx43, as well as brain cells from Cx43 
knockout mice (Cx43Ko cells). Cx43 did not affect the 
ability of Src to decrease Robo1 expression at the 
mRNA level. As shown in Figure 1b, results from 
qRT-PCR revealed that both Src transformed Cx43Ko 
and wild type cells expressed less than half as much 
Robo1 mRNA as nontransformed cells. However, in 
contrast to mRNA expression, Src appeared to augment 
Robo1 protein expression in both Cx43Ko and wild 
type cells by about 2 fold (Figure 1c-1d).  
Taken together, qRT-PCR and protein analyses 
indicate that Src decreased Robo1 mRNA levels while 
increasing Robo1 protein levels (Figure 1a-1c). These 
data suggest that Src can stabilize Robo1 protein in 
transformed cells. To investigate this, we measured the 
effects of the protein
 synthesis inhibitor cyclohexamide 
on the stability of Robo1 in nontransformed and Src 
transformed cells. After 24 hours of cyclohexamide 
treatment, about 75% of Robo1 remained in Src 
transformed cells compared to about 40% in 
nontransformed cells (Figure 2a). Thus, Src appeared 
to increase Robo1 protein stability in transformed cells 
by about 2 fold.  
As shown in Figure 2b, Robo1 was found at the 
membrane of Src transformed cells where it may act as 
a functional receptor to promote tumor cell migration 
and invasion. In addition, a Robo1-GFP fusion 
construct was also utilized to examine the location of 
Robo1 in nontransformed and Src transformed cells. 
As seen in Figure 2c, this Robo1-GFP protein was 
found mostly at the plasma membrane of Src 
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Fig. 2: Src stabilizes Robo1 protein which localizes to the plasma membrane. 
(a) Protein from cyclohexamide treated nontransformed cells, Src transformed cells, and Src transformed cells
treated with the Abl kinase blocker GNF-2 were analyzed by Western blotting to evaluate the effects of Src and
Abl on Robo1 protein stability. Data are shown as the percent of Robo1 protein after 24 hours of cyclohexamide
treatment compared to untreated controls (mean+SEM, n=2). (b) Immunofluorescence microscopy was used to
visualize Robo1 (green) and nuclei (blue) in Src transformed cells. DIC images and merged images are also
shown as indicated (bar = 20 microns). (c) GFP tagged Robo1 was visualized by fluorescence microscopy in
nontransformed cells, Src transformed cells, and Src transformed cells treated with GNF-2. DIC images are also
shown as indicated (bar = 20 microns). Double asterisks indicate p values less than 0.01 compared to controls
(by t-test).   
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transformed cells. In contrast, Robo1-GFP was found 
more diffusely through the cytoplasm in 
nontransformed cells and transformed cells treated with 
an Abl kinase blocker (GNF-2), as discussed below. 
 
Src utilizes Robo1 to promote cell migration 
 
Src transformed Cx43Ko and wild type cells 
achieved similar levels of anchorage independence (see 
Figure 3a and 3b). In addition, Src significantly 
increased the motility of both Cx43Ko and wild type 
cells. Src transformed Cx43Ko and wild type cells 
migrated about 3 fold and 6 fold more than 
nontransformed cells, respectively (Figure 3c and 
Fig. 3: Src utilizes Robo1 to promote cell migration. 
Cells obtained from wild type (WT) or homozygous null Cx43 knockout (Cx43Ko) mouse embryos were
transfected with v-Src or the empty parental vector and plated (10,000 per well) were plated on standard or ultra
low attachment culture dishes to evaluate (a) anchored and (b) nonanchored cell growth. Cell numbers were
determined by Coulter counter at the indicated time points for anchored cells or at 7 days for nonanchored cells.
Data are shown as number of cells per well at the indicated time points (mean+SEM, n=3).  (c) Cell migration
was examined by a wound healing assay on nontransformed cells and Src transformed cells treated with IgG
control antiserum, R5 antiserum to block Robo1 activity, or GNF-2 Abl kinase blocker. Migration was quantitated
as the number of cells that entered a 1.8 mm2 area of the wound during 24 hours (mean+SEM, n=5). (d) Src
transformed cells were treated with R5 antibody or control antiserum and analyzed by Western blotting for
Robo1, active N-WASP (p-N-WASP), or β-actin. N-WASP activity was then quantitated and shown as percent of
untreated control cells (mean+SEM, n=2). Experiments were performed with Cx43Ko and WT cells, with results
from Cx43Ko cells shown in panel d. Double and triple asterisk indicate p values less than 0.01 and 0.005
compared to controls, respectively (by t-test). 
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Supplementary Figure S1).  
As mentioned above, Slit2/Robo1 signaling can 
promote glioma cell migration [30] and metastasis of 
breast cancer cells to the brain [31]. We utilized a 
neutralizing antibody (R5 Ab) to examine the effects of 
Robo1 on the motility of Src transformed cells. This 
monoclonal antibody targets the first immunoglobulin 
domain of Robo1 to block activation of Robo1 
signaling [14,19]. As described above, Src significantly 
increased the migration of Cx43Ko and wild type cells. 
As shown in Figure 3c, application of R5 Robo1 
antiserum suppressed the migration of these Src 
transformed cells by at least 2 fold. As shown in Figure 
1c, in contrast to mRNA levels, Src transformed cells 
actually expressed less Slit2 protein than 
nontransformed cells. In addition, conditioned medium 
from Src transformed cells did not affect the migration 
of nontransformed cells, indicating that Slit2 induction 
was not sufficient to account for the increased 
migration of Src transformed cells (see Supplementary 
Figure S2). Thus, these data indicate that Src 
augmented Robo1, but not Slit2, production to promote 
tumor cell migration. However, the data also clearly 
indicate that Robo1 induced migration in a Slit2 
dependent manner.  
 
Src activates Abl to augment Robo1 expression and 
GTPase activity. 
 
Many axon guidance receptors, including Robo1, 
regulate the Rho family of GTPases to affect cell 
motility. N-WASP is an effector through which Rho 
GTPases regulate the actin cytoskeleton [7]. Effects of 
R5 antiserum are also evident on N-WASP activity. 
Application of the R5 antiserum reduced N-WASP 
activity by over 60% (Figure 3d). 
Robo1 interacts with the Abl kinase to initiate 
cytoskeleton rearrangement [11,32]. However, in 
contrast to this proposed role of Abl as a Robo1 
effector, we hypothesized that Src activates Abl to 
stabilize Robo1 expression in transformed cells. As 
seen in Figure 4a, although Abl protein expression 
levels were similar in both Src transformed and 
nontransformed cells, Src increased the activity of Abl 
in transformed cells by several fold. 
Results from immunoprecipitation studies indicate 
that Robo1 and Abl associate with each other and that 
Robo1 is phosphorylated on tyrosine in Src 
transformed cells. Lysates from Src transformed and 
nontransformed cells were immunoprecipitated with 
anti-Robo1 antiserum and immunoblotted with anti-
Abl antibody. Reciprocal experiments were also 
performed; lysates were immunoprecipitated with anti-
Abl antibody and immunoblotted with anti-Robo1. As 
shown in Figure 4b, results from these experiments 
indicate that Robo1 and Abl associated with each other 
in both Src transformed and nontransformed cells. 
However, as shown in Figure 4b, phosphotyrosine 
residues were detected in Robo1 from transformed 
cells, but not nontransformed cells. These data suggest 
that Src or Abl can phosphorylate Robo1 in 
transformed cells. 
We utilized siRNA and a chemical kinase blocker 
to determine if Src utilized Abl to augment Robo1 
protein expression. As shown in Figure 5, Abl siRNA 
effectively silenced Abl protein expression and kinase 
activity in Src transformed cells by about 70% and 
40%, respectively. This resulted in a similar decrease 
in Robo1 expression. Moreover, treatment of Src 
transformed cells with the Abl kinase blocker GNF-2 
did not affect Abl protein levels, but reduced Abl 
kinase activity by over 90% and, consequently reduced 
Robo1 expression by about 50% (Figure 5).  
Cyclohexamide treatment shown in Figure 2a also 
indicates that Src utilized Abl to stabilize Robo1 at the 
protein level. After 24 hours of cyclohexamide 
treatment, about 75% of Robo1 remained in Src 
transformed cells compared to about 40% in 
nontransformed cells or transformed cells treated with 
the Abl blocker GNF-2 (Figure 2a). As shown in 
Figure 2c, inhibition of Abl kinase activity by GNF-2 
also resulted in intracellular cytoplasmic Robo1 
localization similar to that seen in nontransformed 
cells, as opposed to plasma membrane localization seen 
in Src transformed controls. These data suggest that 
Abl may stabilize Robo1 at the plasma membrane. It 
should be noted that GNF-2 is highly specific for the 
Abl kinase [33], having no detectable effect on Src 
kinase activity at the concentrations used here (see 
Figure 5a). Thus, Robo1 expression at the cell 
membrane appeared to depend on Abl kinase activity 
in Src transformed cells.  
The effects of abrogating Abl kinase activity on cell 
migration were also examined. As shown in Figure 3c 
and Supplementary Figure S1, these data indicate that 
Abl kinase activity promoted the migration of Src 
transformed cells. Src transformed cells treated with 
GNF-2 migrated about 5 fold less than control cells. 
Taken together, these data indicate that Src activated 
Abl to induce Robo1 expression in order to increase 
migration of transformed cells as illustrated in Figure 
6.  
Abl kinase activity has been implicated in the 
progression of non small cell lung cancer [34].  
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Fig. 4: Src associates and activates Abl in transformed cells. 
(a) Western blotting was used to compare the expression of Abl, active Abl, and β-actin in nontransformed and
Src transformed Cx43Ko or wild type (WT) cells. Abl kinase activity was quantitated and shown as percent of
nontransformed cells (mean+SEM, n=2). (b) Protein from nontransformed and Src transformed cells was
immunoprecipitated with either anti-Abl or anti-Robo1 antibody, and analyzed by Western blotting with
antiserum specific for Robo1, Abl, or phosphotyrosine as indicated. Triple asterisks indicate p values less than
0.005 compared to controls (by t-test).  
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Fig. 5: Src activates Abl to augment Robo1 protein levels. 
(a) Src transformed Cx43Ko cells were transfected with siRNA against Abl, or treated with the Abl kinase
blocker GNF-2, and analyzed by Western blotting for Abl, active-Abl, Robo1, active Src, elF4e, and β-actin as
indicated. (b) Abl expression, Abl activity, and Robo1 expression were then quantitated and shown as percent of
control cells (mean+SEM, n=2). Single and triple asterisks indicate p values less than 0.5 and 0.005,
respectively (by t-test).   
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Fig. 6: Schematic diagram illustrating how Src
activates Abl to stabilize Robo1 expression in
order to promote cell migration. This pathway can
be suppressed by reagents that target Abl
production (siRNA), Abl activity (GNF-2), or Robo1
activation (R5 Ab). 
As shown in Figure 7a, NCI-H28 mesothelioma cells 
exhibited robust Abl activity and Robo1 protein 
expression which were reduced by over 80% and 40%, 
respectively, by treatment with GNF-2. As shown in 
Figure 7b, GNF-2 and R5 antiserum reduced NCI-H28 
cell migration by about 50% and 75%, respectively 
(also see Supplementary Figure S3). These studies 
indicate that the Abl kinase can augment Robo1 protein 
levels to promote the migration of mesothelioma cells.  
Robo1 modulates Rho GTPase activity to affect the 
actin cytoskeleton. In particular, Cdc42 and Rac1 
associate with N-WASP to regulate actin remodeling 
leading to filopodia and lamellipodia movement 
required for cell migration [7,31]. As shown in Figure 
3d, Robo1 appeared to activate N-WASP in Src 
transformed cells. We therefore, sought to determine if 
Cdc42 or Rac1 activity were affected during Robo1 
mediated migration of Src transformed cells. As shown 
in Figure 8, while total Cdc42 and Rac1 protein levels 
were not affected, R5 antiserum reduced levels of GTP 
bound Cdc42 and Rac1 by approximately 50%. These 
data are consistent with a role for Cdc42 and Rac1 in 
tumor cell migration mediated by Robo1.  
 
DISCUSSION 
 
Src and Abl are non-receptor tyrosine kinases that 
play critical roles in tumor cell migration leading to 
invasion and metastasis [5,34]. Activities of these 
kinases have been associated with many types of 
human cancers, including tumors of the colon, breast, 
pancreas, lung, blood, and brain [34,35]. Indeed, Src 
and Abl kinase inhibitors may serve as 
chemotherapeutic medicines [36-39]. 
Studies have implicated Robo1 in liver, breast, and 
brain cancers [30,31,40,41]. Moreover, Robo1 
signaling can augment tumor angiogenesis [13,22]. 
Plattner et al. have reported that Src activates the Abl 
kinase to promote cell migration [2]. In addition, 
studies suggest that the Abl kinase associates with 
Fig. 7: Src activates Abl to promote Robo1 expression and migration of human mesothelioma
cells. 
(a) Western blotting was used to compare the expression of active Abl, Robo1, and β-actin in NCIH28
mesothelioma cells treated with R5 antiserum to block Robo1 activity or GNF-2 Abl kinase blocker. Abl kinase
activity and Robo1 levels were quantitated and shown as percent of nontransformed cells (mean+SEM, n=2).
(b) Cell migration was examined by a wound healing assay on NCIH28 cells treated with GNF-2 or R5 antibody,
as well as controls, as indicated. Migration was quantitated as the number of cells that entered a 1.8 mm2 area
of the wound during 24 hours (mean+SEM, n=5). Double and triple asterisk indicate p values less than 0.01 and
0.005, respectively (by t-test).  
a. Abl and Robo1 in NCIH28 cells                                 b. NCIH28 cell migration
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Robo1 [11,32,42]. However, actual mechanisms by 
which Src, Abl, and Robo1 work together to promote 
cell migration have not been defined. Here, we provide 
evidence that Robo1 plays an important role in tumor 
cell migration induced by Src and Abl. 
Many axon guidance receptors including Robo1 
regulate the Rho family of GTPases to effect changes 
in motility. Rho GTPases are members of the Ras 
superfamiliy. There are over 20 mammalian Rho 
GTPases [43]. When bound to GTP, these GTPases 
target effectors to modify the actin cytoskeleton. In 
particular, 3 Rho GTPases, Rho, Rac, and Cdc42 
activate members of the Wiskott-Aldrich syndrome 
proteins (WASPs) and WASP verprolin homologous 
proteins (WAVEs) which, in turn, activate actin 
polymerization factors, including Arp2/3 and formin, 
to cause elongation and branching of actin fibers  [44-
46]. Our data indicate that Slit2 binds to Robo1 in 
order to activate Cdc42 and Rac1 GTPases, which 
leads to N-WASP activation.  
Previous studies suggest that Abl can inhibit Robo1 
signaling [11], and that Robo1 can decrease Cdc42 
activation during axon guidance and neuronal 
migration [7]. However, in contrast to previous 
observations from studies in developing drosophila and 
mouse embryos [7,11], results from our studies 
demonstrate that Src activates the Abl kinase, which in 
turn stabilizes Robo1 protein to increase Cdc42 and 
Rac1 GTPases activity to promote transformed cell 
migration. Indeed, suppression of Abl activity (with 
siRNA or GNF-2) decreased Robo1 protein levels and 
inhibited the migration of transformed cells. In 
addition, inhibition of Robo1 signaling by monoclonal 
antiserum inhibited tumor cell migration without 
affecting Abl kinase activity. As illustrated in Figure 6, 
these studies suggest that monoclonal antibodies and 
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Fig. 8: Robo1 signaling activates Rho GTPases in transformed cells. 
Src transformed cells were treated with R5 antibody or control antiserum (IgG) and examined for total and
activated Cdc42 and Rac1 GTPases in panels a and b, respectively. Western blotting was performed to detect
active (GTP bound) Cdc42 and Rac1, total Cdc42 and Rac1, and GST. Levels of active Cdc42 and Rac1 were
quantitated and shown as the percent of untreated control cells (mean+SEM, n=3). Experiments were performed
with Cx43Ko and wild type cells, with results from Cx43Ko cells shown. Single and triple asterisks indicate p
values less than 0.5 and 0.005, respectively (by t-test).   
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kinase inhibitors may be used to target specific 
components of the Src/Abl/Robo1 pathway to prevent 
tumor cell migration at multiple steps.  
Our data indicate that the induction of cell 
migration by Robo1 is highly regulated. Suppression of 
Robo1 mRNA production by Src, coupled with the 
need for Abl to stabilize Robo1 protein at the plasma 
membrane ensure that cell migration results from a 
response to a combination of appropriate stimuli. Thus, 
two oncogenic kinases, Src and Abl, must work 
together to promote Robo1-mediated cell migration.  
 
MATERIALS AND METHODS 
 
Cells and treatments 
 
Cells obtained from wild type (WT) or homozygous 
null Cx43 knockout (Cx43Ko) mouse embryos were 
transfected with v-Src or the empty parental vector and 
cultured as described [15-18]. For some experiments, 
nontransformed and Src transformed Cx43Ko cells 
were transfected with a Robo1-GFP expression vector, 
which was generated by cloning the entire coding 
region of Robo1 (accession #: AF040990) into the 
Nhe1-Sac1 sites of pEGFP-N1 (Clontech). NCIH28 
mesothelioma cells were obtained from the ATCC. For 
some experiments, cells were treated overnight with 50 
µg/ml cyclohexamide (Sigma, C7698), 60 nM R5 
antibody to the extracellular region of Robo1, 60 nM 
control IgG antibody [14,19], or 40 µM GNF-2 Abl 
kinase inhibitor (Calbiochem, 197221).  
 
Expression microarrays 
 
Gene expression in nontransformed and Src 
transformed Cx43Ko cells was examined by 
microarray analysis with Mouse Genome 430 2.0 
Arrays (Affymetrix) as previously described 
[15,16,18]. These arrays contain approximately 45,000 
probe sets which represent over 30,000 genes. Affected 
probe sets displayed a difference of at least 4 fold 
between transformed and nontransformed cells, or at 
least a 2 fold change with p<0.05 by t-test with n=2. 
All comparisons were done with cells from parallel 
cultures to control for variability in reagents or 
experimental conditions. Expression analysis was 
performed with Vector Xpression software 4.0 
(Invitrogen). 
 
siRNA transfection 
 
Small interference RNA (siRNA) targeted to Abl 
(Santa Cruz Biotechnology, SC29844) or siCONTROL 
nontargeting siRNA (Dharmacon
  D00120613) were 
transfected into cells at a final concentration of 100 nM 
with Lipofectamine 2000 (Invitrogen, 12252-011).  
 
qRT-PCR  
 
Total RNA was extracted from cells using TRI 
RNA Isolation Reagent (T9424, Sigma). cDNA was 
then synthesized using Protoscript first strand cDNA 
synthesis Kit (E6500S, BioLabs). Quantitative RT-
PCR amplification of Robo1 and Actin cDNA was 
performed with iQ SYBR Green Supermix (BioRad) 
using primers for Actin (5'-CCCAGAGCAAGAGAGG-3' 
and 5'-GTCCAGACGCAGGAT-3') and Robo1 (5’-
GAGGTAGCTATACTACGGGATGAC-3’ and 5’-
CAGATGTAGTAGCCGACATCAGAC-3’). SYBR 
green emission intensities were measured during the 
amplification reaction with an iCycler detection system 
(Applied Biosystems 7800).   
 
Western blotting and Immunoprecipitation 
 
For co-immunoprecipitation studies, cells were 
lysed in CSK buffer (100mM NaCl, 1.5mM MgCl2, 
10mM pipes pH 6.8) containing 0.5% Triton-X-100, 
1mM sodium vanadate (Sigma, S6508), 1mM PMSF 
(Sigma, P7626), 50mM NaF (Sigma, S7920) and 1% 
Protease inhibitor cocktail for mammalian cells 
(Sigma, P2417).  For phosphotyrosine studies, cells 
were lysed in 20 mM Tris-HCl (pH 6.9) containing 125 
mM
 NaCl, 1 mM EDTA, 1 mM EGTA, 0.75% Triton 
X-100, 1 mM β-glycerolphosphate,
 50 mM NaF, 1 mM 
Na3VO4, 1mM PMSF and 10 µg/ml proteinase 
inhibitor
  mixture (Sigma, catalog number P2714). 
Lysates were clarified by centrifugation and incubated 
with either Robo1 (Santa Cruz
 Biotechnology, 16612) 
or Abl (Santa Cruz Biotechnology, SC 23) at 4
oC 
overnight. Protein A/G (Santa Cruz) or protein G 
(Pierce, 20398) were added and the reaction was 
incubated for an additional 2h. Immune complexes 
were washed with lysis buffer, and eluted by boiling 
the samples in sample buffer (7.5% SDS, 80mM DTT, 
0.25M Tris pH6.8, 8.25% glycerol, 0.01% 
bromophenol blue). Total protein was obtained from 
cells lysed in buffer containing 62.5mM Tris-HCl 
(pH6.8), 50mM DTT, 2% SDS and 10% glycerol. 
Proteins were resolved by gel electrophoresis, 
transferred to Immobilion-P membranes (Millipore 
IPVH00010), and subjected to immunoblotting with  
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antisera specific for Robo1 (Abcam, ab7279), active 
Src kinase (phosphorylated at Y416) (Cell Signaling 
Technology,
  2101), v-Src (Upstate Biotechnologies, 
05-185), Cx43 (BD Transduction Laboratories, 
610061), Abl (Cell Signaling Technologies, 2862), 
active Abl kinase (phosphorylated at Y245) (Cell 
signaling Technologies, 2861S), active N-WASP 
(phosphorylated at S484 and S485) (Chemicon 
International, AB1964), Cdc42 (Abcam, ab41429), 
Rac1 (BD Transduction Laboratories, 610650), elF4E 
(Cell Signaling Technologies, 9742), Slit2 (Millipore, 
O94813),  β-actin (Sigma, A1978), phosphotyrosine 
(Cell Signaling Technology, 9411), or glutathione S-
transferase (GST). Signal was detected with 
appropriate HRP conjugated secondary antibodies and 
ECL reagents (Millipore), and quantitated with ImageJ 
software (NIH, version 1.38x).  
 
Immunofluorescence microscopy 
 
Cells were fixed with 3.7% paraformaldehyde in 
PBS, permeabilized with acetone in PBS, blocked with 
BSA, incubated with anti-Robo1 antibody (Abcam), 
stained with a FITC conjugated goat anti-rabbit 
antibody (Invitrogen, Alexa 488, A-11008), rinsed in 
PBS, and then immersed in PBS containing 1ug/ml 
Hoechst 33258 for 1 min. Images were obtained with a 
Carl Zeiss LSM510 meta confocal microscope 
equipped with a Plan-Apochromat 63X objective. 
Argon (ex:488nm), and UV (ex:364nm) lasers were 
used with appropriate band pass filters (BP:505-530, 
BP:420-480) to detect Alexa 488 and Hoechst 33342 
respectively.  
 
Cdc42/Rac activity assays 
 
Cdc42 activation was measured by affinity
 
precipitation of cellular GTP-bound form of Cdc42 as 
described [20]. Cells were untreated or treated with 
60nM IgG or R5 antibody for 8 hours. Cells were lysed 
(50 mM Tris, pH 7.4, 1% Triton X-100,
 150 mM NaCl, 
10 mM MgCl2, 0.5% sodium deoxycholate, 0.1 % 
sodium dodecyl sulfate (SDS),
 10% glycerol, 10 µg/ml 
each of leupeptin and
 aprotinin, and 0.1 mM PMSF) 
and incubated with GST fused to the Cdc42/Rac (p-
21)-binding
  domain of PAK bound to glutathione-
coupled agarose beads (GST-PBD)
 for 90 minutes at 
4°C. The fusion protein beads with bound
  proteins 
were then washed three times in lysis
 buffer, eluted in 
sample buffer and analyzed by western blotting.  
 
Cell growth and migration assays 
 
Cells (10,000 per well) were plated in standard 
tissue culture treated 12-well plates (Falcon, 3043) or 
in ultra low attachment 24-well plates (Corning, 3473) 
to assay anchored and nonanchored growth, 
respectively, as previously described [15,16,18]. Cell 
numbers were determined by Coulter counter at the 
indicated time points. Cell migration was measured by 
a wound healing assay in which confluent layers were 
scratched with a plastic pipette tip, washed with fresh 
medium, and cultured for 24 hours. The number of 
cells entering the wound were counted from phase-
contrast images obtained with a digital camera 
(AxioCam MRm) attached to a Zeiss microscope 
(Axiovert 40 CFL) equipped with Axiovision 4.5 
software as described [21].   
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